NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model
NanoViricides CEO Dr Anil Diwan shares promising news about the company's ultra-broad-spectrum antiviral, NV-387, and its effectiveness in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.
This news highlights the potential of NV-387 as a powerful therapeutic option for treating severe influenza infections and possibly other respiratory viral infections. It is a critical development in the field of antiviral therapies, especially in addressing both current and emerging viral threats.
